N-Heterocyclic Carbenes as Ligands to 198Au(I)-Radiolabeled Compounds: A New Platform for Radiopharmaceutical Design

Uložené v:
Podrobná bibliografia
Názov: N-Heterocyclic Carbenes as Ligands to 198Au(I)-Radiolabeled Compounds: A New Platform for Radiopharmaceutical Design
Autori: Sarah Spreckelmeyer, Sophie R. Thomas, Franziska Schuderer, Catarina I. G. Pinto, Ana Luiza de Andrade Querino, Felix A. Böhm, Mihyun Park, Christopher Geppert, Christian Gorges, Filipa Mendes, Angela Casini
Zdroj: Journal of Medicinal Chemistry. 68:17516-17526
Informácie o vydavateľovi: American Chemical Society (ACS), 2025.
Rok vydania: 2025
Predmety: 301305 Medical chemistry, Heterocyclic Compounds/chemistry, Methane/analogs & derivatives, 104020 Radiochemistry, Ligands, 301207 Pharmazeutische Chemie, Article, ddc, Gold/chemistry, 104020 Radiochemie, SDG 3 - Good Health and Well-being, Drug Design, SDG 3 – Gesundheit und Wohlergehen, Imidazoles/chemistry, Radiopharmaceuticals/chemistry, Humans, 104003 Anorganische Chemie, 301207 Pharmaceutical chemistry, 104003 Inorganic chemistry, 301305 Medizinische Chemie
Popis: The radionuclide 198Au, with a half-life of 2.7 days, emits γ radiation ideal for diagnostic purposes and generates β- particles suitable for effective cancer radiotherapy, making it a perfect nuclide for "theranostics". However, the application of coordination compounds of Au(I)/Au(III) in medicine is limited by their instability in vivo. Here, we explore N-heterocyclic carbene (NHC) organometallic chemistry to stabilize 198Au(I) in radiopharmaceuticals. Thus, Au(I) NHC compounds featuring different scaffolds were selected for 198Au radiolabeling. Eventually, two compounds featuring imidazole (AuNHC-1) and theophylline (AuTMX2) scaffolds were successfully radiolabeled (radiochemical purity = 92.9% and 40.2%, respectively). Instead, two peptidic Au(I) benzimidazolylidene derivatives, capable of blood-brain barrier translocation in vitro, were subjected to ligand exchange reactions under the applied radiolabeling conditions. The obtained proof-of-concept results showed that NHCs are suitable ligands to achieve isotope exchange in Au(I) complexes. Overall, our work reveals the still untapped potential of organometallic chemistry in radiopharmaceutical design.
Druh dokumentu: Article
Popis súboru: application/pdf
Jazyk: English
ISSN: 1520-4804
0022-2623
DOI: 10.1021/acs.jmedchem.5c01073
Prístupová URL adresa: https://ucrisportal.univie.ac.at/de/publications/3d892232-6eae-4751-8242-95f3faa8ed61
https://doi.org/10.1021/acs.jmedchem.5c01073
https://mediatum.ub.tum.de/1796552
Rights: CC BY
Prístupové číslo: edsair.doi.dedup.....7d6c41b15d953d10eb6f324efb4ecd24
Databáza: OpenAIRE
Popis
Abstrakt:The radionuclide 198Au, with a half-life of 2.7 days, emits γ radiation ideal for diagnostic purposes and generates β- particles suitable for effective cancer radiotherapy, making it a perfect nuclide for "theranostics". However, the application of coordination compounds of Au(I)/Au(III) in medicine is limited by their instability in vivo. Here, we explore N-heterocyclic carbene (NHC) organometallic chemistry to stabilize 198Au(I) in radiopharmaceuticals. Thus, Au(I) NHC compounds featuring different scaffolds were selected for 198Au radiolabeling. Eventually, two compounds featuring imidazole (AuNHC-1) and theophylline (AuTMX2) scaffolds were successfully radiolabeled (radiochemical purity = 92.9% and 40.2%, respectively). Instead, two peptidic Au(I) benzimidazolylidene derivatives, capable of blood-brain barrier translocation in vitro, were subjected to ligand exchange reactions under the applied radiolabeling conditions. The obtained proof-of-concept results showed that NHCs are suitable ligands to achieve isotope exchange in Au(I) complexes. Overall, our work reveals the still untapped potential of organometallic chemistry in radiopharmaceutical design.
ISSN:15204804
00222623
DOI:10.1021/acs.jmedchem.5c01073